251 related articles for article (PubMed ID: 32953982)
1. Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Kennedy EM; Farkaly T; Grzesik P; Lee J; Denslow A; Hewett J; Bryant J; Behara P; Goshert C; Wambua D; De Almeida A; Jacques J; Deavall D; Rottman JB; Glorioso JC; Finer MH; Haines BB; Quéva C; Lerner L
Mol Ther Oncolytics; 2020 Sep; 18():476-490. PubMed ID: 32953982
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
3. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
4. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
Kuroda T; Martuza RL; Todo T; Rabkin SD
BMC Biotechnol; 2006 Sep; 6():40. PubMed ID: 16995942
[TBL] [Abstract][Full Text] [Related]
5. Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1.
Chouljenko DV; Murad YM; Lee IF; Delwar Z; Ding J; Liu G; Liu X; Bu X; Sun Y; Samudio I; Jia WW
Mol Ther Oncolytics; 2023 Mar; 28():334-348. PubMed ID: 36938544
[TBL] [Abstract][Full Text] [Related]
6. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
7. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
8. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.
Ruiz AJ; Hadac EM; Nace RA; Russell SJ
J Virol; 2016 Apr; 90(8):4078-4092. PubMed ID: 26865716
[TBL] [Abstract][Full Text] [Related]
10. Herpes Simplex Virus 1 Lytic Infection Blocks MicroRNA (miRNA) Biogenesis at the Stage of Nuclear Export of Pre-miRNAs.
Pan D; Li G; Morris-Love J; Qi S; Feng L; Mertens ME; Jurak I; Knipe DM; Coen DM
mBio; 2019 Feb; 10(1):. PubMed ID: 30755517
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells.
Li JM; Kao KC; Li LF; Yang TM; Wu CP; Horng YM; Jia WW; Yang CT
Virol J; 2013 Jul; 10():241. PubMed ID: 23876001
[TBL] [Abstract][Full Text] [Related]
12. Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects.
Thomas SK; Lilley CE; Latchman DS; Coffin RS
J Virol; 1999 Sep; 73(9):7399-409. PubMed ID: 10438830
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
16. Characterization of herpes simplex virus 2 primary microRNA Transcript regulation.
Tang S; Bosch-Marce M; Patel A; Margolis TP; Krause PR
J Virol; 2015 May; 89(9):4837-48. PubMed ID: 25673716
[TBL] [Abstract][Full Text] [Related]
17. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
18. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
19. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.
Lilley CE; Groutsi F; Han Z; Palmer JA; Anderson PN; Latchman DS; Coffin RS
J Virol; 2001 May; 75(9):4343-56. PubMed ID: 11287583
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
